Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5427045 | 0.85 | MAPT (0.36) | KCNH2ALDH1A1SLC2A1MEN1KMT2A | |
| SCHEMBL5318472 | 0.78 | KCNH2 (0.37) | KCNH2ALDH1A1LMNASLC2A1ACHE | |
| SCHEMBL5430770 | 0.78 | KCNH2 (0.36) | KCNH2ALDH1A1SLC2A1MEN1KMT2A | |
| SCHEMBL5430773 | 0.78 | KCNH2 (0.36) | KCNH2ALDH1A1SLC2A1MEN1KMT2A | |
| SCHEMBL5316283 | 0.77 | CXCR4 (0.43) | KCNH2LMNASLC2A1 | |
| SCHEMBL5263439 | 0.77 | KCNH2 (0.40) | KCNH2SLC2A1ACHE | |
| SCHEMBL5432619 | 0.76 | KCNH2 (0.48) | KCNH2SLC2A1 | |
| SCHEMBL5439543 | 0.75 | KCNH2 (0.58) | KCNH2SLC2A1 | |
| SCHEMBL5445713 | 0.75 | SUV39H2 (0.40) | KCNH2ALDH1A1 | |
| SCHEMBL5432623 | 0.75 | KCNH2 (0.34) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244103-A1 | Novel Compounds Having an Anti-Bacterial Activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-10-18 | — | — | US | disclosed |
| EP-1781650-A1 | NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006021448-A1 | NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244103-A1 | Novel Compounds Having an Anti-Bacterial Activity | TOP1, TOP2A, TOP2B | KCNH2 3363/4885ALDH1A1 3625/4885LMNA 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.